Waldemar von Zedtwitz

Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission

Retrieved on: 
Tuesday, February 8, 2022
SARS, GLOBE, Tavistock, Iwasaki, PACE, Severe acute respiratory syndrome coronavirus 2, Hoffmann-La Roche, Yale University, ACE2, Organic acid, Technology, Gastrointestinal tract, Howard Hughes Medical Institute, RSV, Company, Cellular, Vaccination, Infection, Developmental Biology (journal), Patient, Jonathan Edwards College, Faculty, Hospital, Pancreas, RNA transfection, Biomedical engineering, Â, COVID, Death, Biomedicine, Center, Waldemar von Zedtwitz, Head, Institute of Health and Biomedical Innovation, Nose, Vaccine, Bone marrow, Doctor of Philosophy, Immunity, COVID-19, Chemical substance

NEW HAVEN, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Xanadu Bio, a privately held company focusing on next generation delivery of mRNA and other nucleic acids, today announced a broad exclusive license agreement from Yale University for a next generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed options with Yale University for the intranasal delivery of PACE/Spike mRNA and Spike recombinant proteins for the development of mucosal immunity in the nasosinus.

Key Points: 
  • Additionally, the company has executed options with Yale University for the intranasal delivery of PACE/Spike mRNA and Spike recombinant proteins for the development of mucosal immunity in the nasosinus.
  • Xanadu is developing an intranasal SARS-CoV-2 vaccine booster, after systemic vaccination, to protect against infection in the nasosinus/upper airways, thus potentially reducing SARS-CoV-2 transmission in the community.
  • Prime and Spike and Prime and PACE (with Spike mRNA), are novel intranasal vaccine booster strategies, which are covered under Xanadus agreement with Yale University.
  • Leveraging PACE, Xanadu is initially focused on developing nasal vaccine boosters for the prevention and treatment of SARS CoV-2 infection and for other indications.

BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

Retrieved on: 
Tuesday, September 21, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Novartis Institute for Tropical Diseases, Therapy, Infection, Vertically transmitted infection, Developmental Biology (journal), Vaccine, SAB, Howard Hughes Medical Institute, Merck & Co., National, University, Coronavirus Scientific Advisory Board (Turkey), Wyeth, Virus, Senior, Immunology, Merck, Company, LLC, Columbia University, Biological Technologies Office (DARPA), COVID-19, Research, Anthrax, RSV, Degenerative disease, International Medical Education Directory, Food, Massachusetts Institute of Technology, Waldemar von Zedtwitz, Urinary tract infection, Biomedical Research, HSV, MedImmune, Massachusetts, Department, Pharmaceutical industry

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.

Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
  • The members of the BlueWillow Biologics SAB include:
    Robin Isaacs, M.D.
  • Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
  • We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.